Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,354.40 +121.18 0.80%
S&P 500 1,667.47 +17.00 1.03%
Nasdaq 3,498.97 +33.72 0.97%
Ticker Volume Price Price Delta
STOXX 50 2,817.99 +11.29 0.40%
FTSE 100 6,723.06 +35.26 0.53%
DAX 8,398.00 +28.13 0.34%
Ticker Volume Price Price Delta
Nikkei 15,138.10 +100.88 0.67%
Hang Seng 23,082.70 +38.44 0.17%
S&P/ASX 200 5,180.77 +15.11 0.29%
  • Fund Type: Closed-End Fund
  • Objective: Sector Fund-Health & Biotech
  • Asset Class: Equity
  • Geographic Focus: Global

BB Biotech AG

+ Add to Watchlist

BION:SW

121.4000 CHF 1.6000 1.34%

As of 13:17:31 ET on 05/17/2013.

Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Snapshot for BB Biotech AG (BION)

Open: 119.8000 High - Low: 121.4000 - 119.8000 Primary Exchange: SIX Swiss Ex
Volume: 14,276 52-Week Range: 69.7890 - 122.8000 Beta vs NBI: 0.8265

ETF Chart for BION

No chart data available.
  • BION:SW 121.4000
  • 1D
  • 1M
  • 1Y
119.8000
Interactive BION Chart

Previous Close

Fund Profile & Information for BION

BB Biotech AG is an investment company. The Company invests in biotech companies that operate in areas that include oncology, cardiovascular diseases, infectious diseases and autoimmune diseases.

Inception Date: 1993-11-16 Telephone: Tel: +41 44 267 67 00
Managers: DANIEL KOLLER
Web Site: www.bbbiotech.ch/en/bb-biotech/

Fundamentals for BION

NAV (on 2013-05-16) 152.2500
Assets (M) (on 2002-12-31) 1,579.0000
Shares out (M) 13.00
Market Cap (M) 1,578.20
% Premium -21.31
Average 52-Week % Premium -21.8661
Fund Leveraged N

Dividends for BION

Dividend Type Return of Capital
Dividend Frequency Annual
Last Dividend Net (on 2013-03-20) 4.5000
Dividend Yield (ttm) 3.71%

Performance for BION

1-Month +16.17% 1-Year +61.12%
3-Month +28.53% 3-Year +28.01%
Year To Date +42.91% 5-Year +11.81%
Expense Ratio 1.02

Top Fund Holdings for BION

Filing Date: 03/31/2012
Name Position Value % of Total
Celgene Corp 2,600,000 181,900,000 16.293%
Actelion Ltd 4,226,115 139,500,000 12.496%
Vertex Pharmaceuticals Inc 2,822,684 104,500,000 9.360%
Gilead Sciences Inc 4,220,000 93,000,000 8.330%
Incyte Corp Ltd 4,980,000 86,700,000 7.766%
Novo Nordisk A/S 591,056 73,900,000 6.619%
Isis Pharmaceuticals Inc 7,233,800 57,200,000 5.124%
Halozyme Therapeutics Inc 4,800,000 55,300,000 4.953%
Amylin Pharmaceuticals LLC 2,323,391 52,300,000 4.685%
ImmunoGen Inc 3,666,300 47,600,000 4.264%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Financial Commentaries

Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil